The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director
Insilico Medicine, a global leader in end-to-end AI-powered drug discovery, announced the appointment of Steven Galson, MD, MPH as the independent member of the board of directors.
August 12, 2021
by prnasia
Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine
Insilico Medicine announced that its AI-powered drug discovery platform had delivered the preclinical candidate ("PCC") for kidney fibrosis.
August 5, 2021
by prnasia
Insilico Medicine and Usynova Announce Strategic Partnership on Accelerating R&D of Small Molecule Innovative Drugs with AI
Insilico Medicine, an industry leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, and Usynova announced to reach strategic cooperation in advancing the development of novel therapies.
August 5, 2021
by prnasia
Insilico Medicine and Westlake Pharma Announce Cooperation Relationship on Accelerating the Innovative Drugs R&D for Novel Coronavirus
Insilico Medicine and Westlake Pharma announced a strategic partnership to jointly develop innovative small-molecule drugs for Novel Coronavirus (COVID-19) today.
August 3, 2021
by prnasia
GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership
GenFleet Therapeutics and Insilico Medicine announced to reach strategic partnership in advancing development of novel therapies today.
July 21, 2021
by prnasia
Insilico enters into a collaboration with APRINOIA to apply novel generative AI-powered system to discover novel compounds for neurodegenerative diseases
Insilico Medicine is pleased to announce that it has entered into a research collaboration with APRINOIA Therapeutics to utilize Insilico's novel generative artificial intelligence (AI) technology to accelerate the discovery of next generation ...
December 30, 2020
by prnasia
Insilico and Boehringer to use AI for drug targets discovery
Boehringer partners Insilico for AI-based discovery of drug targets. Insilico Medicine has partnered with Boehringer Ingelheim.
April 16, 2020
by pharmaceutical-technology
Insilico Opens Subsidiary in Boston
The Boston subsidiary´s prime location is within the largest biopharmaceutical hub in the US.
March 3, 2020
by contractpharma
Insilico Medicine develops new AI drug discovery system
Insilico Medicine has developed an artificial intelligence (AI)-powered system to facilitate the creation of therapeutic molecules.
September 4, 2019
by pharmaceutical-technology
Insilico, ARK initiate health-span and longevity partnership
Insilico Medicine has announced the beginning of a partnership with Ageing Research at King’s (ARK), a new world-class multi-disciplinary center for ageing research formed at King's College London.
May 28, 2019
by pharmatimes
Insilico opens office in Singapore to expand biz in Asia
Insilico Biotechnology plans to attract data scientists in APAC for exciting roles at the intersection of data science and biotechnology
April 16, 2019
by biospectrumasia
Insilico, Juvenescence and the Buck Institute form AI-based venture to tackle metabolism and aging-related diseases
A triumvirate of aging-focused biotechs and researchers—the AI company Insilico Medicine, the portfolio-based startup Juvenescence and the nonprofit Buck Institute—have formed a new joint venture to develop small molecules for a novel target in a bid to e
August 15, 2018
by fiercebiotech